Fresenius Medical Care invests €312 million in Interwell Health, reinforcing its commitment to value-based care and enhancing its leadership in the renal care market.

Information on the Target

Interwell Health (IWH) is a leading player in the renal value-based care sector, partnering with over 2,200 nephrologists across the United States. This organization has established itself as a pivotal force in delivering high-quality kidney care, facilitating streamlined patient outcomes, and optimizing costs for healthcare providers. Since the merger with Cricket Health and Fresenius Health Partners in August 2022, IWH has experienced substantial growth, achieving a revenue of €1,035 million in just the first half of 2025, exhibiting an impressive revenue growth of 23.5% during this period.

As part of Fresenius Medical Care's broader strategy, IWH is poised to enhance its operational framework and improve patient care outcomes. The recent share acquisition solidifies Fresenius Medical Care's commitment to expanding its influence and capabilities within value-based care, making it a strategic asset for delivering more accessible kidney care solutions.

Industry Overview in the Target's Specific Country

The healthcare landscape in the United States is undergoing a substantial shift towards value-based care, which focuses on improving patient outcomes while managing costs. As part of this transformation, healthcare providers are increasingl